CClinicalTrials.gg
CompletedNCT02451163Fib-CC-2014Updated Apr 12, 2016

DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly

A Phase 2 interventional study of wheat polysaccharides and maltodextrin in Upper Respiratory Infections and Common Cold, sponsored by Clinical Research Center Kiel GmbH. Completed at 1 site in Germany. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-12.

Sponsored by Clinical Research Center Kiel GmbH · Phase 2, Interventional, and Prevention

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The aim of the study is to measure the effect of wheat polysaccharides on the occurence of common cold (CC) in elderly during a 12-week consumption period.

Read the detailed description

The study is conducted in the frame of the collaborative project 'FibeBiotics' (No. 289517) (Fibers as support of the Gut and Immune function of Elderly - From polysaccharide compound to health Claim) within the Seventh Framework Programme (FP7) for Research and Technological Development of the European Union (EU).

02

Conditions studied

03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 247 is above the median of 120 across 4,200 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Clinical Research Center Kiel GmbH is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • men and postmenopausal women aged ≥ 50
  • willingness to abstain as far as possible from food and supplements containing probiotics, prebiotic supplements, other fermented products, supplements containing vitamins and minerals as well as willingness to sustain a low dietary fibre diet for 14 weeks
  • written informed consent

Exclusion criteria

Exclusion Criteria:

  • subjects currently enrolled in another clinical study
  • subjects having finished another clinical study within the last 4 weeks before inclusion
  • surgery or intervention requiring general anaesthesia within 2 months before the study
  • current symptoms of common infectious diseases (CID) of the airways or other organ systems e.g. gastrointestinal tract
  • history of allergic rhinitis, allergic asthma, anaphylactic shock, quincke edema, food allergy (type I allergy)
  • allergy or hypersensitivity to any component of the test product (e. g. wheat, corn)
  • known congenital, acquired or iatrogenic immunodeficiency (e.g. HIV, chemotherapy, immunosuppression)
  • active autoimmune diseases
  • severe chronic disease (COPD, respiratory insufficiency, cancer, IBD, malabsorption, malnutrition, chronic inflammatory diseases, severe renal, hepatic or cardiac diseases)
  • known coeliac disease (gluten enteropathy)
  • chronic systemic or chronic topical treatment likely to interfere with evaluation of the study parameters: antiallergic drugs, antibiotics, intestinal or respiratory antiseptics, anti-rheumatics, antiphlogistics (except aspirin or equivalent products preventing from aggregation of platelets or blood clotting) and steroids prescribed in chronic inflammatory diseases (in the last 4 weeks before inclusion)
  • diabetes mellitus
  • other chronic treatments likely to interfere with study outcome: e.g. laxatives, body weight management and/or medication
  • chronic abdominal pain
  • bowel movement less than 3 times per week
  • subjects, who meet 2 or more Rome III criteria for constipation or who take laxatives on a regular basis
  • vegetarian, vegan diet
  • eating disorders (e.g. anorexia, bulimia)
  • alcohol and drug abuse
  • severe neurological, cognitive or psychiatric diseases
  • subjects not understanding or speaking fluently German
  • legal incapacity
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
247 participants (actual)

Study arms

  • Active comparator
    polysaccharides from wheat

    12.0 g powder containing 10.0 g active ingredient (wheat polysaccharides) as well as 2.0 g filling substance (maltodextrin) stirred in milk or filtered apple juice (200 ml each).

    Dietary Supplement: wheat polysaccharides

  • Placebo comparator
    control product

    12.0 g maltodextrin stirred in milk or filtered apple juice (200 ml each).

    Dietary Supplement: maltodextrin

Interventions

  • Dietary supplementwheat polysaccharides

    Consumed once daily for 12 weeks.

  • Dietary supplementmaltodextrin

    Consumed once daily for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Occurrence of common cold (CC) based on Jackson et al. 1958 and physicians diagnosis

    Occurrence of common cold (= number of subjects affected by at least one common cold episode during intervention) according to self-reporting (questionnaire based on Jackson et al. 1958) and physicians diagnosis.

    Time frame: 12 weeks

Secondary outcomes

  1. Cumulative severity of common cold episodes

    Cumulative severity of common cold episodes (= sum of daily symptom scores acc. to Jackson et al. 1958).

    Time frame: 12 weeks

07

Study locations

1 site
  • Clinical Research Center (CRC) Kiel GmbH
    Kiel, Schleswig-Holstein 24118, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02451163
Lead sponsor
Clinical Research Center Kiel GmbH
Collaborators
BioActor, European Commission
Responsible party
Sponsor
First posted
May 21, 2015
Start date
Sep 2014
Primary completion
Dec 2015
Completion
Mar 2016
Last update
Apr 12, 2016

Study contacts

Christiane Laue, MD
principal investigator · Clinical Research Center Kiel GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion